Chasteberry (vitex) Vitex agnus-castus L.
Also called: vitex, chaste tree, monk's pepper, agnus castus, gattilier
Chasteberry comes from the chaste tree, a shrub of the Mediterranean and Central Asia. EU-assessed medicines use the dried fruit or fruit extracts; other products may use leaves, stems, flowers or seeds.
- Category
- Botanical
- Part used
- Fruit (other products: leaves, stems, flowers, seeds)
- Strongest evidence
- B Some positive trials
- Native range
- Native from the Mediterranean to Central Asia and India (northwest Rajasthan)
- Reviewed
- 2026-10-28
Class 1 Well studied in people. A 2013 systematic review (Planta Medica) of Vitex extracts as the sole agent included 12 RCTs: 8 in premenstrual syndrome, 2 in premenstrual dysphoric disorder and 2 in latent hyperprolactinemia; results were not pooled. [5]
Fact-checked 2026-10-28 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| Premenstrual syndrome (PMS), including breast pain | B | Several studies of low-to-moderate quality suggest chasteberry might reduce PMS symptoms such as breast pain or tenderness; higher-quality evidence is needed. [1] |
| Premenstrual syndrome: one specific dry extract | B | In a placebo-controlled study of 178 women, a specific dry extract improved irritability, mood changes, anger, headache and breast fullness; the EU accepts it as well-established use for PMS. [3] |
| Heavy menstrual bleeding with an IUD | C | One study suggested a reduction, but the evidence is of low quality. [1] |
| Infertility and sexual dysfunction | C | There isn't enough reliable evidence to know whether chasteberry helps; it may be unsafe during pregnancy. [1] |
| Menopausal symptoms | C | In combination with St. John's wort, chasteberry was ineffective for menopausal symptoms. [2] |
Main constituents: Flavonoids including casticin and apigenin; diterpenes such as clerodadienols and rotundifuran with dopaminergic activity in vitro [2]
Amounts studied and limits
Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.
- One particular dry extract taken continuously for 3 months for PMS (EU well-established use). [3]
No official upper intake level has been set.
Safety and side effects
- Liver (NIH LiverTox)Score EABCDEA: well known causeE: unlikely cause
LiverTox likelihood score E (unlikely cause of clinically apparent liver injury), chapter updated 2023-01-20.
Details and sources - Pregnancy and breastfeedingEU monograph: no data from use in pregnant women; use is not recommended during pregnancy. Reproductive studies suggest it may affect lactation …
3 statements in the profile.
Details and sources - Interactions with medicines4 listed
Dopamine agonists, dopamine antagonists, estrogens and antiestrogens; Antipsychotics and antiparkinson agents …
Details and sources - Cancer evaluations (IARC, NTP)None found
No IARC or NTP evaluation was found in the lists checked.
Details and sources - FDA new dietary ingredient notificationsNone on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographsStated
EU (HMPC monograph, Revision 1, dated 27 March 2018), female adults.
Details and sources
- Generally well tolerated short term; fruit extract has been used safely in studies for up to 3 months. Side effects are usually mild: nausea, stomach pain, diarrhea, headache or itching. [1]
- May not be safe for women with hormone-sensitive conditions such as breast, uterine or ovarian cancer; use during pregnancy or breastfeeding may be unsafe. [1]
- Reported side effects include severe allergic reactions with face swelling and difficulty breathing or swallowing, rash, acne, dizziness and menstrual disorders; their frequency is unknown. [3]
Interactions
| With | What happens |
|---|---|
| Antipsychotics (dopamine D2 antagonists) | Preclinical studies suggest chasteberry may interfere with these drugs or enhance their side effects; clinical relevance has yet to be determined. [2] |
| Antiparkinson drugs (dopamine agonists) | Preclinical studies suggest possible interference or enhanced side effects; clinical relevance has yet to be determined. [2] |
| Oral contraceptives and hormone therapies | Preclinical studies suggest chasteberry may decrease their effects; clinical relevance has yet to be determined. [2] |
| CYP2C19 and CYP3A4 substrates | Chasteberry inhibits these enzymes in vitro and may affect drugs they metabolize; clinical relevance has yet to be determined. [2] |
Tell a pharmacist or doctor about every supplement you take. All documented interactions in this hub.
Regulatory status
- US: herbal products for oral use are often marketed as dietary supplements, which, unlike drugs, are not approved by the FDA before sale; manufacturers are responsible for safety and labeling. [1]
- EU: one dry fruit extract has well-established use for PMS; other agnus castus fruit preparations have traditional use for minor premenstrual symptoms. Use is limited to adult women. [3]
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
- Flavonoids, glycosides, organic acids, alkaloids, essential oils, diterpenoids and sterols; LiverTox states the active ingredient is unknown Mixed constituent classes [P1]
- Casticin and apigenin Flavonoids [P2]
- Clerodadienols (dopaminergic compounds that dose-dependently inhibited pituitary prolactin release) and rotundifuran (modulates dopamine receptors) Diterpenes [P2]
US status
What FDA's published records show. FDA does not approve dietary supplements.
- No NDI notification naming chasteberry (Vitex agnus-castus) was found in FDA's published NDI list (dated July 9, 2026; checked 2026-10-29). FDA keeps no authoritative list of ingredients marketed before October 15, 1994. [P3]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
Liver (NIH LiverTox)
- LiverTox likelihood score E (unlikely cause of clinically apparent liver injury), chapter updated 2023-01-20. Single case reports of liver injury with jaundice reported to manufacturers did not adequately exclude other diagnoses. [P1]
Interactions with medicines
- Dopamine agonists, dopamine antagonists, estrogens and antiestrogens: EU monograph: no interactions reported, but because of possible dopaminergic and estrogenic effects, interactions cannot be excluded; users of these medicines should consult their doctor. [P6]
- Antipsychotics and antiparkinson agents: Preclinical data suggest interference or enhanced side effects. [P2]
- Oral contraceptives and hormonal therapies: Preclinical data suggest decreased effects. [P2]
- CYP2C19 and CYP3A4 substrates: In vitro inhibition of CYP2C19 and CYP3A4; clinical relevance has not been determined. [P2]
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- No published information found in the sources checked.
Adulteration and substitution
- A 2016 review describes PCR-RFLP and multiplex ARMS DNA methods and LC-MS markers (two characteristic diterpenes of agnus castus fruit and a triterpene derivative specific to shrub chaste tree fruit) developed to authenticate the botanical origin of Vitex products, in response to concerns about ingredient substitution. [P7]
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity: at least one appropriate test or examination of each component that is a dietary ingredient — Required by 21 CFR 111.75(a)(1)(i) for every dietary-ingredient component; an exemption may be requested by petition under 21 CFR 10.30. [P8]
- Conformity with the European Pharmacopoeia monograph for agnus castus fruit (Ph. Eur. 2147) — The EU herbal monograph states that the material complies with Ph. Eur. monograph 2147. [P6]
- Botanical-origin authentication (DNA methods or LC-MS diterpene markers) — Methods were developed to distinguish agnus castus fruit from related Vitex material because of substitution concerns. [P7]
Supply and conservation
Absorption in people
- No published information found in the sources checked.
Formulations studied to change absorption
Human data only.
- No published information found in the sources checked.
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- EU (HMPC monograph, Revision 1, dated 27 March 2018), female adults. Well-established use (premenstrual syndrome): 20 mg dry extract (DER 6–12:1, ethanol 60% m/m) once daily; continued use over three months is stated. Traditional use (minor symptoms in the days before menstruation): powdered fruit 400 mg twice daily (800 mg/day); tincture 1:5 (ethanol 68–70%) 165 mg once daily; dry extract DER 7–13:1 4 mg once daily; dry extract DER 10.0–18.5:1 2–3 mg once daily. Not recommended under 18 years. [P6]
Pregnancy and breastfeeding
- EU monograph: no data from use in pregnant women; use is not recommended during pregnancy. Reproductive studies suggest it may affect lactation; use during lactation is not recommended. [P6]
- NCCIH: use during pregnancy or while breastfeeding may be unsafe. [P10]
- LiverTox: because of possible hormonal effects, use is not recommended in pregnant or breastfeeding women or in women on birth control or hormone replacement. [P1]
Sources for this profile
- NIH LiverTox (NIDDK). Chaste Tree (Last Update: 2023-01-20), 2023-01-20. ncbi.nlm.nih.gov
- Memorial Sloan Kettering Cancer Center. About Herbs: Chasteberry (last updated December 9, 2021), 2021-12-09. mskcc.org
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- IARC Monographs. Agents Classified by the IARC Monographs: List of Classifications (accessed 2026-10-29), 2026-10-29. monographs.iarc.who.int
- National Toxicology Program (NIEHS). Technical Reports list (accessed 2026-10-29), 2026-10-29. ntp.niehs.nih.gov
- European Medicines Agency, HMPC. European Union herbal monograph on Vitex agnus-castus L., fructus, Revision 1 (EMA/HMPC/606742/2017, dated 27 March 2018), 2018-03-27. ema.europa.eu
- Masada S. Authentication of the botanical origin of Western herbal products using Cimicifuga and Vitex products as examples. J Nat Med 2016;70(3):361-75 (PMID 27188194), 2016-07. pubmed.ncbi.nlm.nih.gov
- eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (up to date as of 10/23/2026), 2026-10-23. ecfr.gov
- GBIF species API: IUCN Red List category for Vitex agnus-castus L., 2026-10-29. api.gbif.org
- NCCIH. Chasteberry: Usefulness and Safety (Last Updated: April 2025), 2025-04. nccih.nih.gov
Sources
- NCCIH. Chasteberry: Usefulness and Safety (Last Updated: April 2025), 2025-04. nccih.nih.gov
- Memorial Sloan Kettering Cancer Center. About Herbs: Chasteberry (Last Updated December 9, 2021), 2021-12-09. mskcc.org
- European Medicines Agency, HMPC. Agni casti fructus (agnus castus fruit) - herbal medicinal product (monograph revision 1 published 10/10/2018), 2018-10-10. ema.europa.eu
- Plants of the World Online (POWO), Royal Botanic Gardens, Kew; WCVP data (Govaerts et al., Sci Data 2021). Vitex agnus-castus L. (accessed 2026-10-28; Kew cannot warrant the accuracy of the data). powo.science.kew.org
- van Die MD, et al. Vitex agnus-castus extracts for female reproductive disorders: a systematic review of clinical trials. Planta Med 2013;79(7):562-75 (PMID 23136064), 2012-11-07. pubmed.ncbi.nlm.nih.gov
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in botanical: Aloe vera · American ginseng · Amla · Andrographis · Arjuna · Arnica · Aronia (black chokeberry) · Asafoetida · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.